Skip to main content

Table 1 Participant characteristics by Cohorts (n = 400)

From: Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points

  Cohort 1
n = 200
Cohort 2
n = 200
Total
n = 400
p-value
Group size 200 (50%) 200 (50%) 400 (100%)  
Gender (male) 117 (58%) 119 (60%) 236 (59%) 0.839
Age (years)a 38 (28–48) 35 (28–44) 36 (28–46) 0.059b
Ethnicity
- Australian 152 (76%) 137 (68%) 289 (72%) 0.056
- Asian 20 (10%) 14 (7%) 34 (8%)
- Pacific Islander 13 (6%) 23 (12%) 36 (9%)
- Other 15 (8%) 26 (13%) 41 (10%)
Admissions (last 12 months)
- One or two 157 (78%) 165 (82%) 322 (80%) 0.582
- Three or four 27 (14%) 21 (10%) 48 (12%)
- Five or more 16 (8%) 14 (7%) 30 (8%)
Hospital duration (days)a 8 (4–17) 10 (5–22) 9 (5–19) 0.317c
Primary diagnosis
- Schizophrenia 72 (36%) 76 (38%) 148 (37%) 0.946
- Bipolar disorder 27 (14%) 26 (13%) 53 (13%)
- Other psychotic disorder 30 (15%) 32 (16%) 62 (16%)
- Other 71 (36%) 66 (33%) 137 (34%)
Comorbid substance use disorder 77 (38%) 46 (23%) 123 (31%) 0.001
Involuntary treatment 77 (38%) 84 (42%) 161 (40%) 0.475
Previous clozapine trial 23 (12%) 20 (10%) 43 (11%) 0.628
  1. n (%) shown unless otherwise noted
  2. amedian and inter-quartile range (25th and 75th percentiles) shown; p-values calculated with chi-squared test unless otherwise noted
  3. bWilcoxon rank-sum test
  4. cmedian test